Investigating prostate medication effects on gut microbiota

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the relationship between prostate medications and gut microbiota in men with prostatic hyperplasia and prostate cancer. It will assess how hormonal therapies, such as 5-alpha reductase inhibitors and LHRH antagonists, influence gut microbiota composition and metabolic characteristics. The study will also evaluate how gut microbiota may affect patients' responses to these medications. Participants will receive specific dosages of medications while their gut microbiota and metabolic profiles are monitored over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provision of signed and dated informed consent form.
* Ability and stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

* Any history of a fecal transplantation.
* Recent (within 3 months or still symptomatic) gastroenteritis.
* Antibiotic treatment within 3 months (expect for antibiotic prophylaxis related to prostate biopsies).
* Inability to comply with the protocol of unwillingness to participate in the study.

Where it's running

• Turku University Hospital
  Turku, Finland Recruiting
• University of Turku
  Turku, Finland Recruiting

Study contacts

• Study coordinator: Peter Bostrom, MD, FEBU
• Email: peter.bostrom@tyks.fi
• Phone: +35823135925

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using a new type of PET scanner for imaging prostate cancer and related conditions

  This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.

  Recruiting Jagiellonian University · Krakow · NCT06242119

• Profiling imaging factors in prostate cancer treatment outcomes

  This study is trying to see if special MRI scans can help doctors better understand and treat prostate cancer in men aged 18 and older.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03354416

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.